Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments

Donna Reece, Giovanni Piza Rodriguez, Mariela Pantoja, Darrell White, Christopher P. Venner, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin W. Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger Tiedemann, Christine Chen, and Harminder Paul

Blood 2016 128:4632;
MRD negativity has become an important goal of the initial treatment of MM pts. Our phase 2 multi-center clinical trial, conducted in 10 major Canadian transplant centers, was designed to increase the MRD negativity rate after ASCT by using conditioning with 2 high dose alkylating agents followed by len maintenance. In addition to conventional response criteria, this trial evaluated serial bone marrow aspirate (BMA) samples for MRD analysis by 8–color multiparameter flow cytometry (MFC) along with serum Hevylite™ assays of the involved HLC that were obtained before and after ASCT and during maintenance therapy.

After bortezomib (btz)–based induction therapy off study, pts without MM progression received BuMel (busulfan 3.2 mg/kg IV days -5 to -3 or days -6 to -4 + melphalan 140 mg/m² day -2 or day -3) conditioning, followed by ASCT on day 0. On day 100 post–ASCT, len 10 mg/day was started, escalated after 3 cycles to 15 mg/day if appropriate, and continued until progression. BMA and serum samples were shipped centrally for MRD and Hevylite analysis before induction therapy, before ASCT, on day 100 post–ASCT, every 3 mos for the 1st year and every 6 mos until progression.

Between 03/2013 – 05/2016, 125 newly diagnosed pts provided BMA samples for MRD analysis. To date, 76 pts (target 78), have completed induction therapy and undergone ASCT; 2 pts have provided initial samples and are expected to be enrolled. 46 of the 125 (36.8%) who provided BMA samples did not proceed to BuMel due to: poor samples – 4 (3.2%); MM not confirmed – 3 (2.4%); prior therapy – 1 (0.8%); death during induction – 1 (0.8%); consent withdrawal/opted for standard conditioning – 21 (16.8%); and no ASCT – 16 (12.8%) (8 were unfit, 4 had comorbidities, 2 progressed, 1 failed mobilization and 1 underwent preferential tandem ASCT). Median follow–up is 27.4 mos (range: 10.4–37.6).

Median age is 57 (34–69); 65.8% are male. Median serum β2–microglobulin level is 3.07 mg/L (1.5–20) and albumin 37 g/L (2.8–48.1); 34 pts have ISS stage I; 21 stage II; 17 stage III MM and 5 have missing data. Ig isotype includes IgGκ in 34 (44.7%), IgGλ in 16 (21.1%), IgAλ in 10 (13.2%), IgAκ in 9 (11.8%) and κ in 7 (9.2%).

Post–ASCT, 26 SAEs have occurred: Grade 2: atrial fibrillation (1) and URI (1); Grade 3: atrial fibrillation (1), acute kidney injury (4), infectious enterocolitis (2), gallbladder infection (1), URI (1), febrile neutropenia (3), bacteremia (1), pain in extremity (1), hypoxia (1), pleural effusion (1), and 3 lung infection (4); and Grade 4: sepsis (1), AML [with spontaneous regression] (1), respiratory distress (1) and acute kidney injury (1). There have been no ASCT–related deaths; 11(14.4%) pts have progressed.
The best conventional Ig response post-induction in the 76 evaluable pts is CR in 6 (7.9%), VGPR in 29 (38.2%), PR in 35 (46.1%), MR in 5 (6.6%) and SD in 1 (1.3%). At day 100 after ASCT, the Ig response in the 73 evaluable pts is CR in 9 (12.3%), VGPR in 41 (56.2%), PR in 22 (30.1%) and MR in 1 (1.4%). The rates of MRD negativity also increased from 29% after btz-based induction to 41%, while the rates of achievement of a normal HLC ratio were 50% after induction and 48% at day 100 (Table 1). Among evaluable pts, 77.3% of those after induction and 53.3% of those at day 100 who were MRD-negative also had had normal involved HLC ratios, while 38.9% and 44.2% of those, who were MRD-positive, respectively, had had normal involved HLC ratios. At month 6 and 12 post-ASCT, 43% and 35% of evaluable pts, respectively, are MRD-negative. Individual patient patterns of len dose, MRD negativity and involved HLC ratios are under assessment and will be presented.

**Conclusions:** 1) IV BuMel conditioning + ASCT is well-tolerated with few SAEs and no ASCT-related deaths; 2) at day 100 post-ASCT, 98.6% had achieved ≥ PR (≥ VGPR in 68.5% and CR in 12.3%); 3) MRD negativity rates improved from 29% to 41% after ASCT; 4) the rates of normalization of the involved HLC ratio remained stable (50% to 48%) pre- and post-ASCT; 4) conventional Ig and MRD responses were often discordant as only 41% of CR pts were MRD-negative at day 100; 5) the majority of MRD-negative patients (53.3%) also had normalization of their involved HLC ratios; 5) with a median follow-up of over 2 years, only 14% of pts have progressed; 6) the serial marrow samples mandated by this study will allow determination of relationships between len dose, conventional Ig response rates, MRD status and involved HLC ratios as these pts are followed for longer periods of time.
Disclosures

Reece: **Takeda**: Consultancy, Honoraria, Research Funding; **Otsuka**: Honoraria, Research Funding; **Merck**: Research Funding; **BMS**: Honoraria, Research Funding; **Janssen**: Consultancy, Honoraria, Research Funding; **Novartis**: Honoraria, Research Funding; **Amgen**: Consultancy, Honoraria, Research Funding; **Celgene**: Consultancy, Honoraria, Research Funding. **White**: Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; **Celgene**: Consultancy, Honoraria.

Venner: **Takeda**: Honoraria; **Celgene**: Honoraria, Research Funding; **J+J**: Research Funding; **Janssen**: Honoraria; **Amgen**: Honoraria.
Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTMÂ chain (HLC) Normalization
Jean Roy et al., Blood

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): Updated Results Including S


* Asterisk with author names denotes non-ASH members.

© 2016 by The American Society of Hematology

Potential Articles of Interest

Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum HevyliteTMÂ chain (HLC) Normalization
Jean Roy et al., Blood

PTH-072 Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated with Vedolizumab
E Loftus et al., Gut

PTH-052 Efficacy of Vedolizumab with and Without Continued Immunosuppressant Use in Gemini 1 and Gemini 2
B Feagan et al., Gut

FRI0451 Secukinumab Provides Rapid and Sustained Reductions in Dactylitis and Enthesitis in Patients with Psoriatic Arthritis: Analysis of Data from The Phase 3 Randomised, Multicentre, Double-Blind, Placebo-Controlled Future 2 Study

www.bloodjournal.org/content/128/22/4632
Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Hevylite
Jean Roy et al., Blood

First Report of the Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide Maintenance: Feasibility of a National Canadian Study Based on Achievement of Minimal Residual Disease (MRD) Negativity
Kevin Song et al., Blood

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial
Meletios A Dimopoulos et al., Blood

Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma
Laura Rosinol Dachs et al., Blood

B. Kirkham et al., Ann Rheum Dis

FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study
P Nash et al., Ann Rheum Dis

P138 An innovative approach to study design: using electronic medical records to inform the feasibility and design of the novelty study (a novel observational longitudinal study on patients with asthma and/or copd)
Thorax

Powered by TRENDMD

Back to top

Advertisement
Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including S...
Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including S...